losartan has been researched along with Vascular Diseases in 11 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the ability of poststroke captopril and losartan treatment to reverse myogenic and endothelial dysfunction in the middle cerebral arteries of Kyoto-Wistar stroke-prone spontaneously hypertensive rats (SHRsp) that developed intracerebral hemorrhagic stroke." | 7.74 | Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. ( McGuire, JJ; Smeda, JS, 2007) |
| "Losartan treatment for 4-8 weeks reduced blood pressure of SHR to the normal levels seen in WKY." | 5.36 | Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. ( Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010) |
| " (Cucurbitaceae) is one of the most valued plant species to treat cardiovascular diseases, including hypertension." | 3.88 | Acetone fraction from Sechium edule (Jacq.) S.w. edible roots exhibits anti-endothelial dysfunction activity. ( Arrellín, G; Barrita-Cruz, GJ; Castro-Martínez, G; Fragoso, G; Hernández, B; Jiménez-Ferrer, JE; Lombardo-Earl, G; Medina-Campos, ON; Méndez-Martínez, M; Pedraza-Chaverri, J; Ramírez, CC; Rosas, G; Santana, MA; Trejo-Moreno, C; Zamilpa, A, 2018) |
| "We assessed the ability of poststroke captopril and losartan treatment to reverse myogenic and endothelial dysfunction in the middle cerebral arteries of Kyoto-Wistar stroke-prone spontaneously hypertensive rats (SHRsp) that developed intracerebral hemorrhagic stroke." | 3.74 | Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. ( McGuire, JJ; Smeda, JS, 2007) |
| "Losartan treatment for 4-8 weeks reduced blood pressure of SHR to the normal levels seen in WKY." | 1.36 | Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension. ( Cai, J; Chen, B; Fang, F; Geng, YJ; Huang, X; Qu, J; Shi, X; Wang, S; Yang, D; Zhang, M, 2010) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| "Losartan or placebo treatment was initiated two days before balloon injury in the SHR aorta." | 1.31 | Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury. ( deBlois, D; Hamet, P; Lemay, J, 2000) |
| "Hydrochlorothiazide treatment did not prevent the hyperuricemia or arteriolopathy despite controlling blood pressure." | 1.31 | Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. ( Chen, Q; Feng, L; Gordon, KL; Han, L; Johnson, RJ; Kanellis, J; Kang, DH; Lan, HY; Mazzali, M; Nakagawa, T; Watanabe, S; Xia, YY, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trejo-Moreno, C | 1 |
| Castro-Martínez, G | 1 |
| Méndez-Martínez, M | 1 |
| Jiménez-Ferrer, JE | 1 |
| Pedraza-Chaverri, J | 1 |
| Arrellín, G | 1 |
| Zamilpa, A | 1 |
| Medina-Campos, ON | 1 |
| Lombardo-Earl, G | 1 |
| Barrita-Cruz, GJ | 1 |
| Hernández, B | 1 |
| Ramírez, CC | 1 |
| Santana, MA | 1 |
| Fragoso, G | 1 |
| Rosas, G | 1 |
| Yang, D | 1 |
| Zhang, M | 1 |
| Huang, X | 1 |
| Fang, F | 1 |
| Chen, B | 1 |
| Wang, S | 1 |
| Cai, J | 1 |
| Shi, X | 2 |
| Qu, J | 1 |
| Geng, YJ | 1 |
| Wang, Y | 2 |
| Fu, W | 1 |
| Wang, H | 1 |
| Liang, Y | 1 |
| Yao, W | 1 |
| Chen, W | 1 |
| Li, Q | 1 |
| Ying, PH | 1 |
| Peng, W | 1 |
| Guerrot, D | 1 |
| Dussaule, JC | 1 |
| Mael-Ainin, M | 1 |
| Xu-Dubois, YC | 1 |
| Rondeau, E | 1 |
| Chatziantoniou, C | 1 |
| Placier, S | 1 |
| Richter, MH | 1 |
| Richter, H | 1 |
| Barten, M | 1 |
| Schramm, D | 1 |
| Gummert, J | 1 |
| Mohr, FW | 1 |
| Skupin, M | 1 |
| Olbrich, HG | 1 |
| Graninger, M | 1 |
| Reiter, R | 1 |
| Drucker, C | 1 |
| Minar, E | 1 |
| Jilma, B | 1 |
| Smeda, JS | 1 |
| McGuire, JJ | 1 |
| Zhu, WW | 1 |
| Liu, XP | 1 |
| Wu, N | 1 |
| Zhao, TT | 1 |
| Zhao, Y | 1 |
| Zhang, J | 1 |
| Shao, JH | 1 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 1 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
| Lemay, J | 1 |
| Hamet, P | 1 |
| deBlois, D | 1 |
| Mazzali, M | 1 |
| Kanellis, J | 1 |
| Han, L | 1 |
| Feng, L | 1 |
| Xia, YY | 1 |
| Chen, Q | 1 |
| Kang, DH | 1 |
| Gordon, KL | 1 |
| Watanabe, S | 1 |
| Nakagawa, T | 1 |
| Lan, HY | 1 |
| Johnson, RJ | 1 |
1 trial available for losartan and Vascular Diseases
| Article | Year |
|---|---|
Angiotensin receptor blockade decreases markers of vascular inflammation.
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Cholesterol; Double-Blind Method; E-Selectin; Enal | 2004 |
10 other studies available for losartan and Vascular Diseases
| Article | Year |
|---|---|
Acetone fraction from Sechium edule (Jacq.) S.w. edible roots exhibits anti-endothelial dysfunction activity.
Topics: Acetone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cinnamates; | 2018 |
Protection of retinal vasculature by losartan against apoptosis and vasculopathy in rats with spontaneous hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Endothelium, Vascular; | 2010 |
Renal microvascular injury in chronic aristolochic acid nephropathy and protective effects of Cozaar.
Topics: Animals; Aristolochic Acids; Chronic Disease; Kidney; Kidney Diseases; Losartan; Male; Microvessels; | 2012 |
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy.
Topics: Animals; Biomarkers; Blood Pressure; Cell Adhesion Molecules; Disease Progression; Gene Expression R | 2012 |
Angiotensin II type 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Diseas | 2002 |
Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp.
Topics: Animals; Antihypertensive Agents; Captopril; Cerebrovascular Circulation; Endothelium, Vascular; Los | 2007 |
Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Endothelial Cells; Gene Expression Regulation; | 2007 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |
Losartan-induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury.
Topics: Animals; Aorta, Thoracic; Apoptosis; Catheterization; DNA Fragmentation; Endothelium, Vascular; Hype | 2000 |
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
Topics: Administration, Oral; Allopurinol; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Con | 2002 |